Heparin-induced thrombocytopenia

Last updated: September 12, 2024

Heparin-induced thrombocytopenia

RHS

RHS

Viral structure and functions
Rhinovirus
Adenovirus
Influenza virus
Human parainfluenza viruses
Respiratory syncytial virus
Staphylococcus aureus
Streptococcus viridans
Streptococcus pyogenes (Group A Strep)
Streptococcus pneumoniae
Corynebacterium diphtheriae (Diphtheria)
Enterococcus
Upper respiratory tract infection
Allergic rhinitis
Bacillus anthracis (Anthrax)
Nocardia
Enterobacter
Yersinia enterocolitica
Pseudomonas aeruginosa
Klebsiella pneumoniae
Legionella pneumophila (Legionnaires disease and Pontiac fever)
Bacteroides fragilis
Yersinia pestis (Plague)
Moraxella catarrhalis
Francisella tularensis (Tularemia)
Bordetella pertussis (Whooping cough)
Haemophilus influenzae
Pasteurella multocida
Mycobacterium tuberculosis (Tuberculosis)
Mycobacterium leprae
Mycobacterium avium complex (NORD)
Mycoplasma pneumoniae
Chlamydia pneumoniae
Coxiella burnetii (Q fever)
Epstein-Barr virus (Infectious mononucleosis)
Human herpesvirus 6 (Roseola)
Human herpesvirus 8 (Kaposi sarcoma)
Parvovirus B19
Mumps virus
Measles virus
Zika virus
Rubella virus
Candida
Plasmodium species (Malaria)
Asthma: Clinical
Pneumonia
Pneumonia: Pathology review
Respiratory distress syndrome: Pathology review
Restrictive lung diseases
Restrictive lung diseases: Pathology review
Sarcoidosis
Hypersensitivity pneumonitis
Obstructive lung diseases: Pathology review
Tuberculosis: Pathology review
Type IV hypersensitivity
Bartonella henselae (Cat-scratch disease and Bacillary angiomatosis)
Sinusitis
Laryngitis
Retropharyngeal and peritonsillar abscesses
Bacterial epiglottitis
Congenital pulmonary airway malformation
Acute respiratory distress syndrome
Emphysema
Asthma
Bronchiectasis
Cystic fibrosis
Alpha 1-antitrypsin deficiency
Chronic bronchitis
Idiopathic pulmonary fibrosis
Lung cancer
Superior vena cava syndrome
Pancoast tumor
Pneumothorax
Mesothelioma
Pleural effusion
Pulmonary embolism
Pulmonary hypertension
Pulmonary edema
Cystic fibrosis: Pathology review
Deep vein thrombosis and pulmonary embolism: Pathology review
Pleural effusion, pneumothorax, hemothorax and atelectasis: Pathology review
Apnea, hypoventilation and pulmonary hypertension: Pathology review
Lung cancer and mesothelioma: Pathology review
Iron deficiency anemia
Beta-thalassemia
Alpha-thalassemia
Sideroblastic anemia
Anemia of chronic disease
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Autoimmune hemolytic anemia
Sickle cell disease (NORD)
Aplastic anemia
Folate (Vitamin B9) deficiency
Vitamin B12 deficiency
Acute intermittent porphyria
Hemophilia
Hemolytic-uremic syndrome
Thrombotic thrombocytopenic purpura
Immune thrombocytopenia
Von Willebrand disease
Disseminated intravascular coagulation
Heparin-induced thrombocytopenia
Hodgkin lymphoma
Non-Hodgkin lymphoma
Chronic leukemia
Acute leukemia
Myelodysplastic syndromes
Polycythemia vera (NORD)
Myelofibrosis (NORD)
Essential thrombocythemia (NORD)
Mastocytosis (NORD)
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Coagulation disorders: Pathology review
Platelet disorders: Pathology review
Mixed platelet and coagulation disorders: Pathology review
Thrombosis syndromes (hypercoagulability): Pathology review
Lymphomas: Pathology review
Leukemias: Pathology review
Plasma cell disorders: Pathology review
Myeloproliferative disorders: Pathology review
Bronchioles and alveoli histology
Trachea and bronchi histology
Lung volumes and capacities
Alveolar surface tension and surfactant
Ventilation
Zones of pulmonary blood flow
Regulation of pulmonary blood flow
Pulmonary shunts
Ventilation-perfusion ratios and V/Q mismatch
Airflow, pressure, and resistance
Gas exchange in the lungs, blood and tissues
Diffusion-limited and perfusion-limited gas exchange
Blood histology
Blood components
Erythropoietin
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Antimalarials

Transcript

Watch video only

The term heparin-induced thrombocytopenia can be divided into two parts.

Heparin refers to an anticoagulant medication which prevents blood clots from forming, and thrombocytopenia refers to decreased number of thrombocytes, or platelets, in the blood.

So, heparin-induced thrombocytopenia or, HIT, is a complication caused by heparin that results in decreased platelets in the blood.

Okay, so imagine you’re making dinner and accidentally cut one of your fingers.

Now, if your body doesn’t stop the bleeding, you will keep losing blood until there’s not enough to supply the vital organs like the heart and brain.

Now to prevent this from happening the body has a process called hemostasis.

This process has two phases: primary and secondary hemostasis.

In primary hemostasis, platelets aggregate to form a plug at the site of an injured blood vessel.

While these platelets are aggregating, coagulation, or secondary hemostasis starts.

This is where numerous enzymes that are always floating around in the blood called clotting factors get proteolytically activated, meaning that activation happens when a small piece is chopped off - a bit like pulling the pin out of a grenade.

These factors activate one another, eventually leading to the activation of fibrin or factor Ia.

That results in a fibrin mesh which forms around the platelet plug to reinforce it and hold it together.

Without primary and secondary hemostasis, our body would suffer massive blood loss from even the most minor injuries; imagine losing all of your blood from something as simple as a pinprick!

Okay, so heparin induced thrombocytopenia is caused by heparin.

This medication works by activating an enzyme called antithrombin III, which inhibits coagulation factors Xa, also known as thrombin.

This halts secondary hemostasis and prevents existing blood clots from growing larger, so it’s often given to people who suffer from pulmonary embolisms, strokes, and myocardial infarctions.

Now, the main mechanism behind the development of HIT is actually an immune response, which starts when heparin binds to a protein on the surface of inactivated platelets called platelet factor 4 or PF-4. Together they form a complex called heparin-PF4 complex.

This complex is immunogenic in certain people, meaning they have circulating IgG antibodies that recognize the complex as foreign pathogens.

So these antibodies will bind to the heparin-PF4 complex and mark it for destruction within the spleen.

Now when the antibody binds, it causes the platelet to activate.

The activated platelets release procoagulant chemicals like thromboxane A2 or TXA2, which causes other platelets to activate.

At the same time, the original platelet will also release more PF-4s so more antibodies will bind and keep it activated.

These events leads to more and more platelets getting activated and they start forming clots throughout the body.

This way, a lot of the remaining platelets also get consumed, which results in a low platelet count.

Key Takeaways

Heparin-induced thrombocytopenia (HIT) is a rare but potentially life-threatening complication that can occur during the treatment course with heparin. HIT occurs when the body produces antibodies against heparin, which then attach to and damage platelets (the cells that help the blood clot). This can decrease the number of platelets in the blood (thrombocytopenia), which can cause easy bruising and bleeding.

Sources

  1. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  2. "CURRENT Medical Diagnosis and Treatment 2020" McGraw-Hill Education / Medical (2019)
  3. "Yen & Jaffe's Reproductive Endocrinology" Saunders W.B. (2018)
  4. "Bates' Guide to Physical Examination and History Taking" LWW (2016)
  5. "Robbins Basic Pathology" Elsevier (2017)
  6. "Heparin-induced thrombocytopenia: an update" Thrombosis Journal (2005)
  7. "Signaling During Platelet Adhesion and Activation" Arteriosclerosis, Thrombosis, and Vascular Biology (2010)
  8. "von Willebrand Disease in the Pediatric and Adolescent Population" Journal of Pediatric and Adolescent Gynecology (2010)